论文部分内容阅读
目的探讨甲胎蛋白(AFP)、人肝癌抗原(PHCA)和糖链抗原19-9(CA19-9)联合检测对原发性肝癌(HCC)的诊断价值。方法对39例HCC(HCC组)和36例肝硬化患者(肝硬化组),以及40例健康体检者(正常对照组),进行AFP、PHCA和CA19-9三指标检测,分析3项指标对HCC的诊断价值。结果 HCC组血清AFP、PHCA、CA19-9的水平明显高于肝硬化组(P<0.05);三者曲线下面积分别为0.872、0.839、0.649;PHCA的临界值为25.79U/L;HCC组中AFP、PHCA、CA19-9联合检测的诊断敏感性为92.3%,与单项指标的敏感度71.8%、71.8%、61.5%相比,显著增高(P<0.05)。结论 AFP、PHCA、CA19-9三指标联合应用,提高HCC的诊断灵敏度,提高诊断水平。
Objective To investigate the diagnostic value of combined detection of AFP, PHCA and CA19-9 in the diagnosis of primary hepatocellular carcinoma (HCC). Methods Thirty-nine patients with HCC (HCC group), 36 patients with liver cirrhosis (cirrhosis group) and 40 healthy subjects (control group) were enrolled in the study. Three indicators of AFP, PHCA and CA19-9 were detected. HCC diagnostic value. Results The serum levels of AFP, PHCA and CA19-9 in HCC group were significantly higher than those in cirrhosis group (P <0.05). The area under the curve was 0.872, 0.839 and 0.649, respectively. The critical value of PHCA was 25.79U / L. The diagnostic sensitivity of combined detection of AFP, PHCA and CA19-9 was 92.3%, which was significantly higher than the sensitivity of 71.8%, 71.8% and 61.5% (P <0.05). Conclusion AFP, PHCA, CA19-9 three indicators combined to improve the diagnostic sensitivity of HCC and improve the diagnostic level.